Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
Sponsor: Merck Sharp & Dohme LLC
Summary
The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-1403. The study will also measure what happens to MK-1403 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensitivity C-reactive protein (hsCRP) in a person's blood.
Official title: A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1403 in Participants With Type 2 Diabetes Mellitus
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
52
Start Date
2025-12-22
Completion Date
2026-08-28
Last Updated
2026-01-14
Healthy Volunteers
No
Conditions
Interventions
MK-1403 + additive coformulation
MK-1403 + additive coformulation is a co-formulated product of MK-1403 administered orally.
Placebo + additive coformulation
Placebo + additive coformulation is a co-formulated product of placebo administered orally.
Locations (4)
ProSciento Inc. ( Site 0001)
Chula Vista, California, United States
QPS-MRA, LLC ( Site 0004)
Miami, Florida, United States
Advanced Pharma CR, LLC ( Site 0003)
Miami, Florida, United States
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0005)
Springfield, Missouri, United States